% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

richrd_cc 2 posts  |  Last Activity: Jan 28, 2016 11:25 AM Member since: Jan 30, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Filings of 4 and SC 13D/A

    by agatenw Nov 30, 2015 5:45 PM
    richrd_cc richrd_cc Nov 30, 2015 6:32 PM Flag

    I'm just guessing, but... when you have a large loss on paper it is often a great tax move to take those losses and offset them against other capital gains to reduce the overall tax burden. (Even if you do not have large capital gain for the year the losses can offset future capital gains). When he buys the shares back as a trust, (that he probably manages), he retains his controlling ownership and has the same voting power as before.

  • Reply to

    STA-12-8666 news soon.

    by sactownscholar Jan 28, 2016 9:37 AM
    richrd_cc richrd_cc Jan 28, 2016 11:25 AM Flag

    The clinical benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities. Over recent decades, a number of conjugate-based targeting approaches designed to overcome these limitations have been explored. Here, we report on an innovative strategy that utilizes HSP90 inhibitor-drug conjugates (HDC) for directed tumor targeting of chemotherapeutic agents. STA-12-8666 is an HDC that comprises an HSP90 inhibitor fused to SN-38, the active metabolite of irinotecan. Mechanistic analyses in vitro established that high-affinity HSP90 binding conferred by the inhibitor backbone could be exploited for conjugate accumulation within tumor cells. In vivo modeling showed that the HSP90 inhibitor moiety was required for selective retention of STA-12-8666, and this enrichment promoted extended release of active SN-38 within the tumor compartment. Indeed, controlled intratumoral payload release by STA-12-8666 contributed to a broad therapeutic window, sustained biomarker activity, and remarkable degree of efficacy and durability of response in multiple cell line and patient-derived xenograft models. Overall, STA-12-8666 has been developed as a unique HDC agent that employs a distinct mechanism of targeted drug delivery to achieve potent and sustained antitumor effects. These findings identify STA-12-8666 as a promising new candidate for evaluation as novel anticancer therapeutic. Mol Cancer Ther; 14(11); 2422-32. ©2015 AACR

    Sentiment: Strong Buy

0.20-0.01(-4.76%)Feb 5 4:00 PMEST